120
Participants
Start Date
September 15, 2017
Primary Completion Date
April 15, 2020
Study Completion Date
August 19, 2020
Transforaminal ESI with dexamethasone
Catheter-targeted ESI via interlaminar access at the C7-T1 level with dexamethasone sodium phosphate 1.5 mL (10 mg/mL) and 1 ml 1% lidocaine (total volume 2.5 mL).
Transforaminal catheter-targeted ESI with triamcinolone
Catheter-targeted ESI via interlaminar access at the C7-T1 level with triamcinolone acetonide 2 mL (40mg/mL) and 1 ml 1% lidocaine (total volume 3 mL).
Dexamethasone Sodium Phosphate 10 MG/ML
Transforaminal ESI with dexamethasone 1.5 mL of dexamethasone sodium phosphate in group #1
Lidocaine
1 mL of 1% lidocaine as diluent for the steroid in both group #1 and group #2
Triamcinolone Acetonide 40mg/mL
Transforaminal catheter-targeted ESI with triamcinolone acetonide 2 mL in group #2
University of Utah Orthopaedic Center, Salt Lake City
Collaborators (1)
Epimed
INDUSTRY
University of Utah
OTHER